BioStock: FDA grants Cereno Scientific’s lead candidate Orphan Drug Designation

31 March, 2020

Cereno Scientific is accelerating the building of a platform of drug candidates in epigenetic modulation, by HDAC inhibition, for cardiovascular and rare diseases. On March 10, the company’s main candidate CS1 was approved for Orphan Drug Designation by the FDA for the treatment of Pulmonary Arterial Hypertension.

Read the full article on BioStock.